SNX31

Summary

SNX31 (sorting nexin 31, HGNC:28605) is a protein-coding gene on chromosome 8q22.3, encoding Sorting nexin-31 (Q8N9S9). May be involved in protein trafficking.

Predicted to enable phosphatidylinositol binding activity. Predicted to be involved in endocytic recycling and intracellular protein transport. Predicted to be located in cytoskeleton. Predicted to be part of protein-containing complex. Predicted to be active in early endosome.

Source: NCBI Gene 169166 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 11
• Clinical variants (ClinVar): 92 total
• MANE Select transcript: NM_152628

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28605
Approved symbol	SNX31
Name	sorting nexin 31
Location	8q22.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC39715
Ensembl gene	ENSG00000174226
Ensembl biotype	protein_coding
OMIM	619839
Entrez	169166

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000311812, ENST00000428383, ENST00000518342, ENST00000519521, ENST00000520352, ENST00000520661, ENST00000520743, ENST00000862895, ENST00000862896, ENST00000960793, ENST00000960794

RefSeq mRNA: 2 — MANE Select: NM_152628 NM_001363720, NM_152628

CCDS: CCDS6288, CCDS87622

Canonical transcript exons

ENST00000311812 — 14 exons

Exon	Start	End
ENSE00001193755	100596639	100596842
ENSE00001193759	100600349	100600441
ENSE00001193765	100608494	100608563
ENSE00001193767	100612000	100612087
ENSE00001193773	100612995	100613085
ENSE00001193777	100617620	100617730
ENSE00001193787	100649274	100649348
ENSE00001265091	100630327	100630391
ENSE00001265110	100577019	100577075
ENSE00001265163	100572889	100573960
ENSE00001265171	100649449	100649665
ENSE00003473139	100584111	100584188
ENSE00003487029	100635897	100636011
ENSE00003667642	100588866	100588979

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 92.00.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0845 / max 19.2337, expressed in 30 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
94153	0.0389	15
94154	0.0311	14
94152	0.0145	6

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	92.00	gold quality
buccal mucosa cell	CL:0002336	88.57	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.52	gold quality
oral cavity	UBERON:0000167	82.78	gold quality
urinary bladder	UBERON:0001255	81.22	gold quality
epithelium of nasopharynx	UBERON:0001951	78.87	silver quality
endothelial cell	CL:0000115	78.54	silver quality
esophagus squamous epithelium	UBERON:0006920	76.05	gold quality
lower esophagus mucosa	UBERON:0035834	75.31	gold quality
sperm	CL:0000019	74.40	silver quality
esophagus mucosa	UBERON:0002469	73.94	gold quality
pharyngeal mucosa	UBERON:0000355	71.86	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	67.84	gold quality
tonsil	UBERON:0002372	67.44	gold quality
palpebral conjunctiva	UBERON:0001812	64.77	silver quality
esophagus	UBERON:0001043	64.58	gold quality
left testis	UBERON:0004533	64.26	gold quality
right testis	UBERON:0004534	63.75	gold quality
testis	UBERON:0000473	63.37	gold quality
urethra	UBERON:0000057	62.43	silver quality
mucosa of stomach	UBERON:0001199	62.20	gold quality
vagina	UBERON:0000996	60.89	gold quality
ventricular zone	UBERON:0003053	60.63	gold quality
prostate gland	UBERON:0002367	59.60	gold quality
mucosa of paranasal sinus	UBERON:0005030	59.52	gold quality
smooth muscle tissue	UBERON:0001135	59.48	gold quality
bronchial epithelial cell	CL:0002328	58.44	silver quality
bronchus	UBERON:0002185	57.82	silver quality
cerebellar vermis	UBERON:0004720	57.52	gold quality
heart left ventricle	UBERON:0002084	56.88	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

71 targeting SNX31, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-1284	99.67	73.56	1353

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Snx31	ENSMUSG00000013611
rattus_norvegicus	Snx31	ENSRNOG00000025501

Paralogs (2): SNX17 (ENSG00000115234), SNX27 (ENSG00000143376)

Protein

Protein identifiers

Sorting nexin-31 — Q8N9S9 (reviewed: Q8N9S9)

All UniProt accessions (5): Q8N9S9, E5RFI8, E5RJE9, E5RJK2, H0YBA9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in protein trafficking.

Subunit / interactions. Interacts with CCDC22, CCDC93, VPS26C and VPS35L, associates with the retriever and CCC complexes.

Similarity. Belongs to the sorting nexin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N9S9-1	1	yes
Q8N9S9-2	2

RefSeq proteins (2): NP_001350649, NP_689841* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001683	PX_dom	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR036871	PX_dom_sf	Homologous_superfamily
IPR040842	SNX17/31_FERM	Domain
IPR048763	SNX17-31_FERM_F1	Domain
IPR048767	SNX17-31_FERM_F2	Domain

Pfam: PF00787, PF18116, PF21271, PF21273

UniProt features (10 total): sequence variant 3, splice variant 2, sequence conflict 2, chain 1, domain 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N9S9-F1	84.77	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (1):

Position	Phenotype
440	strongly decreases interaction with ccdc22, ccdc93, vps26c and vps35l.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 68 (showing top): GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON, chr8q22, GOBP_ENDOCYTIC_RECYCLING, GOBP_LOCALIZATION_WITHIN_MEMBRANE, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOMF_PHOSPHATIDYLINOSITOL_BINDING, GOMF_LIPID_BINDING, GOMF_PHOSPHOLIPID_BINDING, DODD_NASOPHARYNGEAL_CARCINOMA_DN, MIKKELSEN_ES_ICP_WITH_H3K4ME3, GOBP_ENDOSOMAL_TRANSPORT, GOBP_INTRACELLULAR_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT_TO_THE_PLASMA_MEMBRANE

GO Biological Process (3): intracellular protein transport (GO:0006886), endocytic recycling (GO:0032456), protein transport (GO:0015031)

GO Molecular Function (2): phosphatidylinositol binding (GO:0035091), protein binding (GO:0005515)

GO Cellular Component (3): early endosome (GO:0005769), protein-containing complex (GO:0032991), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	2
protein transport	1
intracellular transport	1
endosomal transport	1
vesicle-mediated transport to the plasma membrane	1
transport	1
establishment of protein localization	1
anion binding	1
binding	1
endosome	1
cellular_component	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

386 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SNX31	WHR1	P49842	697
SNX31	TACC1	O75410	667
SNX31	VPS26C	O14972	628
SNX31	PPP6C	O00743	612
SNX31	VPS29	Q9UBQ0	593
SNX31	RDX	P35241	541
SNX31	VPS35L	Q7Z3J2	539
SNX31	ARID2	Q68CP9	519
SNX31	MSN	P26038	517
SNX31	EZR	P15311	502
SNX31	HRAS	P01112	475
SNX31	SNX8	Q9Y5X2	456
SNX31	SNX3	O60493	452
SNX31	SNX1	Q13596	443
SNX31	DGKZ	Q13574	440

IntAct

7 interactions, top by confidence:

A	B	Type	Score
SNX31	LZTS2	psi-mi:“MI:0915”(physical association)	0.560
LZTS2	SNX31	psi-mi:“MI:0915”(physical association)	0.560
SNX31	ATP5F1A	psi-mi:“MI:0915”(physical association)	0.400
NUDCD2	SNX31	psi-mi:“MI:0915”(physical association)	0.400
TRIM69	POTEF	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): SNX31 (Two-hybrid), SNX31 (Two-hybrid), SNX31 (Affinity Capture-MS), SNX31 (Two-hybrid), SNX31 (Two-hybrid), SNX31 (Proximity Label-MS), SNX31 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GW35, A6QNM3, B0R034, B1ANS9, B9EK06, D2KC46, D3ZY60, F1MS15, F1P065, F1REV3, O00522, O15091, O75747, P10911, P58069, Q008S8, Q14449, Q14D04, Q15283, Q32NR9, Q45GW3, Q4R366, Q4R6T7, Q5H9U9, Q5K651, Q5PQS3, Q5XGX5, Q5XIZ9, Q5ZLD2, Q60862, Q63713, Q69Z37, Q6DCF6, Q6S5J6, Q6TNJ1, Q75PQ8, Q80W71, Q86VD1, Q86YR7, Q8C5W4

Diamond homologs: A5DHC9, Q5AG56, Q6BIS2, Q6FR40, Q6P8Y7, Q8N9S9, Q15036, Q28HD5, Q5EA77, Q5R4A5, Q5RID7, Q6AYS6, Q6DDY6, Q8BVL3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

92 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	73
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3545 predictions. Top by Δscore:

Variant	Effect	Δscore
8:100612621:T:TA	donor_gain	1.0000
8:100612627:A:C	donor_gain	1.0000
8:100613093:C:CT	acceptor_gain	1.0000
8:100613094:A:T	acceptor_gain	1.0000
8:100615201:T:TC	acceptor_gain	1.0000
8:100617613:AGCTT:A	donor_loss	1.0000
8:100617614:GCTT:G	donor_loss	1.0000
8:100617615:CTTA:C	donor_loss	1.0000
8:100617616:TTA:T	donor_loss	1.0000
8:100617617:TA:T	donor_loss	1.0000
8:100617618:A:AT	donor_loss	1.0000
8:100621816:T:TA	donor_gain	1.0000
8:100649454:AGCGG:A	donor_gain	1.0000
8:100649455:G:C	donor_gain	1.0000
8:100573958:CTG:C	acceptor_gain	0.9900
8:100573961:C:CC	acceptor_gain	0.9900
8:100577014:CAGA:C	donor_gain	0.9900
8:100596662:TC:T	donor_gain	0.9900
8:100596860:A:C	acceptor_gain	0.9900
8:100600309:C:CA	donor_gain	0.9900
8:100612085:CAA:C	acceptor_gain	0.9900
8:100612088:C:CC	acceptor_gain	0.9900
8:100612600:A:AC	donor_gain	0.9900
8:100612617:ATATT:A	donor_gain	0.9900
8:100612656:T:TA	donor_gain	0.9900
8:100612985:T:TA	donor_gain	0.9900
8:100617618:A:AC	donor_gain	0.9900
8:100617619:C:CC	donor_gain	0.9900
8:100617619:CCT:C	donor_gain	0.9900
8:100617726:GTATT:G	acceptor_gain	0.9900

AlphaMissense

2924 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:100635928:C:A	R75S	0.991
8:100635928:C:G	R75S	0.991
8:100635929:C:G	R75T	0.982
8:100649285:A:G	W44R	0.982
8:100649285:A:T	W44R	0.982
8:100636010:A:G	L48P	0.979
8:100635976:G:C	F59L	0.978
8:100635976:G:T	F59L	0.978
8:100635978:A:G	F59L	0.978
8:100649303:A:C	Y38D	0.978
8:100613029:A:C	F163L	0.975
8:100613029:A:T	F163L	0.975
8:100613031:A:G	F163L	0.975
8:100649293:A:G	L41P	0.975
8:100635929:C:A	R75M	0.974
8:100635917:A:G	L79P	0.972
8:100635905:A:G	L83S	0.970
8:100635909:A:C	Y82D	0.968
8:100635977:A:G	F59S	0.968
8:100649303:A:G	Y38H	0.968
8:100649302:T:G	Y38S	0.966
8:100635967:C:A	K62N	0.965
8:100635967:C:G	K62N	0.965
8:100649306:G:T	R37S	0.965
8:100649495:A:G	I7T	0.964
8:100635917:A:T	L79Q	0.960
8:100649284:C:G	W44S	0.960
8:100649303:A:T	Y38N	0.957
8:100630345:A:C	F101L	0.956
8:100630345:A:T	F101L	0.956

dbSNP variants (sampled 300 via entrez): RS1000008949 (8:100581937 C>T), RS1000098090 (8:100651877 G>A), RS1000116299 (8:100616424 T>C), RS1000234429 (8:100616182 G>A), RS1000285701 (8:100574798 G>A), RS1000301320 (8:100627063 C>T), RS1000315032 (8:100654344 C>T), RS1000326217 (8:100651443 G>A,C), RS1000354033 (8:100627354 AAAAC>A,AAAACAAAC,AAAACAAACAAAC), RS1000423953 (8:100659953 A>C), RS1000451440 (8:100609553 A>G), RS1000465040 (8:100579837 T>C), RS1000472116 (8:100610392 T>C), RS1000482341 (8:100639399 G>A), RS1000485793 (8:100591054 CAA>C)

Disease associations

OMIM: gene MIM:619839 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST003134_9	Cerebrospinal fluid clusterin levels	3.000000e-06
GCST004280_31	Diastolic blood pressure	2.000000e-09
GCST005714_1	Cerebrospinal fluid beta-site APP cleaving enzyme levels	3.000000e-06
GCST005951_63	Body mass index	2.000000e-08
GCST008155_29	Waist-hip ratio	9.000000e-06
GCST009391_2108	Metabolite levels	2.000000e-07
GCST009391_415	Metabolite levels	7.000000e-06
GCST010703_117	Brain morphology (MOSTest)	3.000000e-18
GCST010726_36	Periventricular white matter hyperintensities	2.000000e-06
GCST011743_48	HDL cholesterol levels in HIV infection	9.000000e-06
GCST011973_1	Colorectal cancer	2.000000e-06

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0009179	beta-secretase 1 measurement
EFO:0004340	body mass index
EFO:0004343	waist-hip ratio
EFO:0010381	phosphatidylcholine 36:3 measurement
EFO:0010387	phosphatidylcholine 38:5 measurement
EFO:0004346	neuroimaging measurement
EFO:0005665	white matter hyperintensity measurement
EFO:0004612	high density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium Chloride	increases abundance, decreases expression	2
bisphenol A	affects cotreatment, decreases methylation	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression, increases abundance	1
Lipopolysaccharides	affects response to substance, increases expression	1
Methapyrilene	increases methylation	1
Silicon Dioxide	affects expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety